FDA gives full approval to Amgen leukemia drug Blincyto
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
Sienna Biopharmaceuticals files for $75 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals filed for an initial public offering with the Securities and Exchange Commission on June 3, stating expectations to raise up to $74.75 million. Founded in 2010, the company develops clinical-stage topical therapies for inflammatory skin diseases and other conditions. ARCH Venture Partners and Venvest Capital led a $40 million Read More →
MannKind hires financial adviser after boosting cash on hand
MannKind, a Southern California biotechnology company heading to Westlake Village, hired Greenhill & Co. as a financial and strategic adviser June 28, after requesting the last of its line of credit through a loan from the Mann Group. The company will draw on the remaining $30.1 million of funding, using $10.6 million to capitalize unpaid Read More →
MannKind moving to former Kythera space in Westlake Village
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
SerImmune gets $8 million in financing from Illumina Ventures
Santa Barbara immunotherapy and diagnostic company SerImmune received $8 million in financing from San Francisco-based Illumina Ventures to expand its immune mapping platform and database. Illumina invests primarily in early-stage companies researching genomics, life science and health care. A subsidiary of pharmaceutical giant Merck also participated in the financing round, alongside other undisclosed investors. Mapping Read More →
Amgen asks FDA to consider new uses for Xgeva
Thousand Oaks-based biotech giant Amgen announced June 19 that the U.S. Food and Drug Administration has accepted a supplemental application for Xgeva (denosumab) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. “Multiple Read More →
Sientra acquisition expands product portfolio
Story updated at 5:45 p.m. June 12: Goleta-based breast implant maker Sientra entered into a $20 million cash agreement to purchase Santa Clara-based Miramar Labs on June 12, according to a news release. Sientra also agreed to potential contingent payments of up to $14 million to Miramar’s debt and equity holders if certain milestones are Read More →
